Although this latter observation was obtained from lymphoid cells, it is consistent with experimental evidence for CML cells, whose mutation rates were observed to be increased by several hundred-fold as compared to parental cells not carrying the BCR-ABL oncogene [37]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.